Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SANGUINATE for Vaso-Occlusive Crises in Sickle Cell Disease
NCT02411708Phase 2Completed
- Sponsor
- Prolong Pharmaceuticals
- Start
- Nov 2016
- Primary completion
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Sanguinate in sickle cell disease (SCD), sponsored by Prolong Pharmaceuticals. Started Nov 2016; status: completed.
02
Drugs
Sanguinate
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02411708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02411708.